Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
55.95
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
October 07, 2024
Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
Exposures
Artificial Intelligence
US Equities
Pfizer Stock Slump: Will Starboard's Billion-Dollar Bet Spark Rebound?
October 07, 2024
Pfizer's stock has struggled due to declining demand for COVID-19 treatments, but activist investor Starboard's $1 billion stake may spark a turnaround.
Via
Benzinga
Exposures
COVID-19
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
October 04, 2024
FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.
Via
Benzinga
Exposures
Product Safety
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
October 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
This Is What Whales Are Betting On Bristol-Myers Squibb
October 01, 2024
Via
Benzinga
2 Passive-Income Stocks to Load Up On in October
October 03, 2024
These two dividend powerhouses are ideal choices for passive-income investors.
Via
The Motley Fool
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
October 03, 2024
A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Via
Investor's Business Daily
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
October 01, 2024
IGM Biosciences shifts focus to autoimmune diseases, reduces oncology research, and appoints former Bristol Myers Squibb executive as CEO. The company aims to extend its cash runway into 2027.
Via
Benzinga
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
September 30, 2024
Changes are afoot at the company, and investors welcomed them.
Via
The Motley Fool
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
September 30, 2024
Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones. The company...
Via
Benzinga
NYSE:BMY Shows Potential for a Breakout.
September 23, 2024
A technical analysis of BRISTOL-MYERS SQUIBB CO (NYSE:BMY) shows it may be setting up for a breakout.
Via
Chartmill
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
September 30, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
3 Surprisingly Underrated Stocks to Buy Right Now
September 28, 2024
These stocks might look like bad picks. But appearances can be deceiving.
Via
The Motley Fool
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
September 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
September 27, 2024
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer option. Analysts project peak sales of up to $5 billion if approved for...
Via
Benzinga
Exposures
Product Safety
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
September 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
14 Stocks Gain Momentum As August Inflation Comes In Below Expectations
September 27, 2024
The Fed's preferred inflation gauge, the PCE Price Index, rose 2.2% YoY, below expectations. Decline in overall inflation suggests an easing of price pressures.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
September 27, 2024
Bristol Myers Squibb's Cobenfy has been approved by the FDA as the first new treatment for schizophrenia in decades. The medication introduces a new approach by targeting M1 and M4 receptors without...
Via
Benzinga
Exposures
Product Safety
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
September 27, 2024
Via
Benzinga
Wall Street On Wait-And-Watch Mode Ahead Of Inflation Data, Bitcoin Holds Above 65.5K: Analyst Says Volatility Ahead Providing Better Entry Point Into Long-term Bull Market
September 27, 2024
Sentiment has soured ahead of the key inflation data that is due ahead of the market open on Friday, with the index futures pointing to a modestly lower opening.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
September 26, 2024
Cobenfy is the first drug to treat the disorder without blocking dopamine.
Via
Investor's Business Daily
Exposures
Product Safety
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
September 25, 2024
The FDA's advisory committee is set to evaluate the use of PD-1 inhibitors in gastric cancer patients, focusing on the risks and benefits for those with varying PD-L1 levels, including low expressers.
Via
Benzinga
Exposures
Product Safety
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
September 25, 2024
2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval...
Via
Benzinga
Exposures
Product Safety
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
September 25, 2024
Edgewise Therapeutics was a massive winner last week after positive results on its cardiovascular treatment. This there still room for the stock to run?
Via
MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
September 20, 2024
KarXT, a novel schizophrenia drug, is on the verge of FDA approval, promising to revolutionize treatment. However, access challenges within the US healthcare system could limit its impact on mental...
Via
Benzinga
Exposures
Product Safety
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
September 19, 2024
Edgewise Therapeutics is trying to edge into a market already owned by Bristol Myers Squibb, just behind Cytokinetics.
Via
Investor's Business Daily
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares.
Via
Investor's Business Daily
Bristol Myers Squibb Presents Data For Multiple Sclerosis Drug Zeposia, Shows Long-Term Efficacy
September 18, 2024
Bristol Myers Squibb announces Phase 3 DAYBREAK trial data showing Zeposia (ozanimod) reduces brain volume loss in relapsing multiple sclerosis patients.
Via
Benzinga
New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis
September 18, 2024
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.